ORIGINAL ARTICLE

Bariatric Surgery and Diabetes: Access Denied

William H. Chapman, Emily Cunningham, and Walter J. Pories

Introduction

THIS YEAR, FOR THE FIRST TIME, we have been provided with strong proof that bariatric surgery is truly effective. Over the last 30 years, there have been multiple reports that the gastric bypass operation provides full remission of diabetes in four out of five people, with a sharp decrease in mortality. Along with the reversal of diabetes, most of those who receive the surgery will also see their high blood pressure, sleep apnea, dyslipidemias, and even their polycystic ovary syndromes clear. Further, within five years, their likelihood of getting various cancers diminishes by more than 70%. Even those who do not experience full remission of their diabetes show marked improvement in control of their disease. Finally, we have developed and demonstrated the success of various bariatric procedures (lap adjustable BAND, gastric bypass, sleeve gastrectomy, and duodenal switch) that have impressive metabolic consequences beyond the remission of diabetes.

In spite of these excellent outcomes widely reported in the surgical literature, *less than one percent of those who could benefit from bariatric surgery have accessed these procedures.*

The skepticism of the medical community is not unwarranted. The claims seem unbelievable; the reports are primarily from surgeons, and the past history of bariatric surgery, a long period of trial and error, includes a number of false and dangerous starts. Accordingly, it is appropriate for physicians, concerned about their patients' safety, to ask if bariatric surgery is really effective, and if it is safe and cost-effective. This year, supported by several key articles cited below, we can answer these questions affirmatively.

Bariatric surgery versus intensive medical therapy in obese patients with diabetes

Schauer PR¹, Kashyap SR², Wolski K³, Brethauer SA¹, Kirwan JP⁴, Pothier CE³, Thomas S¹, Aboud B¹, Nissen SE⁵, Bhatt DL⁶

¹Bariatric and Metabolic Institute, Cleveland Clinic, Cleveland, OH; ²Endocrinology Institute, Cleveland Clinic, Cleveland, OH; ³Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland, OH; ⁴Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH; ⁵Lerner Research Institute,

Cleveland Clinic, Cleveland, OH; ⁶Veterans Affairs Boston Healthcare System, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

N Engl J Med 2012; **366**: 1567–76

Background

Although multiple series have been published documenting the effectiveness of bariatric surgery in the treatment of T2DM, there were no credible prospective randomized series.

Methods

150 obese patients, 66% women, with uncontrolled T2DM with a mean Hb1Ac of $9.2 \pm 1.55\%$ were prospectively randomized to intensive medical therapy, Roux-en-Y gastric bypass, or sleeve gastrectomy.

Results

The proportion of patients in this 12-month study who completed the follow-up was 93%. The proportion of patients with the primary endpoint (Hb1Ac = 6.0%) was 12% (5 of 41 patients) in the medical-therapy group vs. 42% (21 of 50 patients) in the gastric-bypass group ($p = 0.002$) and 37% (18 of 49 patients) in the sleeve-gastrectomy group ($p = 0.008$). Glycemic control improved in all three groups, with a mean glycated hemoglobin level of $7.5 \pm 1.8\%$ in the medical-therapy group, $6.4 \pm 0.9\%$ in the gastric-bypass group ($p < 0.001$), and $6.6 \pm 1.0\%$ in the sleeve-gastrectomy group ($p = 0.003$).

Conclusions

Bariatric surgery is more effective than intensive medical therapy for the treatment of obese patients with uncontrolled T2DM.

Bariatric surgery versus conventional medical therapy for type 2 diabetes

Mingrone G¹, Panunzi S², De Gaetano A², Guidone C¹, Iaconelli A¹, Leccesi L, Nanni G³, Pomp A⁴, Castagneto M³, Ghirlanda G, Rubino F^{3,4}

¹Department of Internal Medicine, Università Cattolica S. Rome, Italy; ²Institute of Systems Analysis and Computer Science (IASI) and BioMatLab, Rome, Italy; ³Department of Surgery, Università Cattolica S. Rome, Italy; and ⁴Section of Gastrointestinal Metabolic Surgery, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY

N Engl J Med 2012; **366**: 1577–85

Background

Prospective randomized trials are needed to answer the question if bariatric surgery is more effective in the treatment of T2DM than intensive medical therapy.

Methods

Sixty patients ages 30–60, BMI ≥ 35 , with a history of at least five years of T2DM, were prospectively randomized to participate in conventional medical therapy or undergo either gastric bypass or biliopancreatic diversion.

Results

At two years, diabetes remission had occurred in no patients in the medical-therapy group vs. 75% in the gastric-bypass group and 95% in the biliopancreatic-diversion group ($p < 0.001$ for both comparisons). Also at two years, the average baseline glycated hemoglobin level ($8.65 \pm 1.45\%$) had decreased in all groups, but patients in the two surgical groups had the greatest degree of improvement (average glycated hemoglobin levels, $7.69 \pm 0.57\%$ in the medical-therapy group, $6.35 \pm 1.42\%$ in the gastric-bypass group, and $4.95 \pm 0.49\%$ in the biliopancreatic-diversion group).

Conclusions

Bariatric surgery was significantly more effective in the control of weight and T2DM than medical therapy.

Bariatric surgery is associated with a reduced risk of mortality in morbidly obese patients with a history of major cardiovascular events

Johnson RJ, Johnson BL, Blackhurst DW, Bour ES, Cobb WS 4th, Carbonell AM 2nd, Lokey JS, Scott JD

Greenville Hospital System University Medical Center, Greenville, South Carolina

Am Surg 2012; **78**: 685–92

Background

There is only sparse data about the long-term survival in patients with cardiovascular disease after bariatric surgery.

Methods

These authors reported a retrospective cohort study of 349 bariatric surgical patients vs. 903 morbidly obese controls with a history of cardiovascular events.

Results

Among bariatric patients, 19 deaths occurred in 986 person-years of follow-up vs. 150 deaths among controls in 3,138 person-years of follow-up. Adjusting for age, comorbidity,

and event history, the relative risk of mortality was reduced by 40% in bariatric patients compared with controls (hazard ratios [95% confidence interval]: 0.60 [0.36, 0.99]). Unadjusted all-cause mortality was estimated at $7 \pm 2\%$ at 5 years in bariatric patients compared with $19 \pm 2\%$ in controls ($p < 0.001$).

Conclusion

In patients with a history of cardiovascular events, bariatric surgery is associated with a significantly decreased risk of all-cause mortality.

Comment

Is the correction of glucose levels by bariatric surgery really important? Does it make a difference in mortality and morbidity?

It may seem curious to ask whether the correction of glucose levels in T2DM is a useful goal, but there is merit in the concern that the correction of glucose laboratory levels cannot be extrapolated to long-term health effects. Actually, this question was addressed before by MacDonald *et al.* (1), who reported that diabetic patients who underwent the gastric bypass had mortality rates 73% lower than a comparable group who did not. The study by Johnson *et al.* confirms that finding.

The answer is clear: Bariatric surgery does reduce mortality in a very high-risk patient cohort. The improvement/remission of diabetes, decrease in hypertension, improved lipid profile, and other still unknown metabolic changes that occur with bariatric surgery all contribute to improved longevity.

Perioperative safety and volume: outcomes relationships in bariatric surgery: a study of 32,000 patients

Gould JC¹, Kent KC², Wan Y², Rajamanickam V², Leverson G², Campos GM²

¹Medical College of Wisconsin, Department of Surgery, Milwaukee, WI; and ²University of Wisconsin School of Medicine and Public Health, Department of Surgery, Madison, WI

J Am Coll Surg 2011; **213**: 771–7

Background

There is no evidence-based data about the association between the amount of yearly bariatric surgical procedures and the medical outcomes.

Methods

The nationwide inpatient sample, 2005–2007, was queried for open and laparoscopic bariatric procedures, complications, and death.

Results

A total of 32,509 bariatric procedures were identified (21% open bypass [Open], 58% laparoscopic bypass [Lap], 21% laparoscopic gastric band [Band]). Inpatient overall mortality was low (total 0.12%, Open 0.3%, Lap 0.09%, Band 0.02%; $p < 0.05$ for all comparisons). Inpatient complications were more prevalent in open procedures (total 3.9%, Open 5.9%, Lap 4%, Band 1.6%;

$p < 0.01$ for all comparisons). For all three procedures, using a combined endpoint of mortality and major complications, a volume-outcomes relationship was evident for hospitals.

Conclusions

The nationwide dataset and bariatric procedure-specific data documents that bariatric surgery mortality and complication rates are very low.

Comment

How safe is bariatric surgery?

With the basic rule of medicine, i.e., “*primum nocere*,” it is mandatory that each of our therapies be carefully examined in terms of safety. This is especially true in the assessment of surgery for the severely obese, a group of patients that all too often enter the operating rooms with anesthesia risk evaluations of three and four due to their comorbidities.

This article reflects the remarkable advances in the safe delivery of bariatric surgery. In the beginning of this century, mortality rates of 10% were not uncommon, and the press was filled with horror stories about “stapled stomachs” and lawsuits. With the advent of laparoscopic procedures, improved equipment and technology, and improved perioperative evaluation and care, the morbidity and mortality of bariatric procedures have diminished. The development of Centers of Excellence by the Association of Metabolic and Bariatric Surgeons (ASMBS), the Surgical Review Corporation (SRC), the American College of Surgeons (ACS), and the National Surgical Quality Improvement Program (NSQIP) has been crucial to insuring good quality programs and outcomes to the point where bariatric surgery is now delivered in over 450 U.S. hospitals with a 90-day mortality of 0.3%, equal to that reported for routine cholecystectomies even though the morbidly severe present with far greater risks.

Healthcare utilization and costs in severely obese subjects before bariatric surgery

Keating CL¹, Moodie ML¹, Bulfone L¹, Swinburn BA², Stevenson CE³, Peeters A^{3,4}

¹Deakin Health Economics, Deakin University, Melbourne, Australia; ²World Health Organization Collaborating Centre for Obesity Prevention, Deakin University, Melbourne, Australia; ³Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia; and ⁴Obesity and Population Health, Baker IDI, Heart and Diabetes Institute, Melbourne, Australia

Obesity (Silver Spring) 2012 May 4; [Epub ahead of print]; DOI: 10.1038/oby.2012.124

Background

It is important to evaluate whether bariatric surgery is cost-effective.

Methods

This study evaluated the healthcare utilization and associated costs for a severely obese population before receiving laparoscopic adjustable gastric banding (LAGB) surgery in

2009 ($n = 11,769$) relative to an age- and sex-matched sample from the Australian general population. Utilization of medical services and pharmaceuticals in the 3.5 years before surgery were ascertained for each severely obese subject through linkage with Medicare, Australia’s universal health insurance scheme. Equivalent data were retrieved for each subject from the matched general population sample ($n = 140,000$).

Results

Severely obese subjects utilized significantly more medical services annually compared to the general population (mean: 22.8 vs. 12.1/person, standardized incidence ratio [SIR]: 1.89 [95% confidence interval (CI) 1.88–1.89]), translating to two-fold higher mean annual costs (Australian \$1,140 vs. \$567/person). The greatest excess costs in the obese related to diabetes drugs, lipid-modifying agents, psychoanaleptics, acid-related disorder drugs, agents acting on the rennin-angiotensin system, immune suppressants, and obstructive airway disease drugs.

Conclusion

Overall, healthcare costs in the severely obese population were more than double those incurred by the general population.

Early postoperative outcomes and medication cost savings after laparoscopic sleeve gastrectomy in morbidly obese patients with type 2 diabetes

Slater BJ¹, Bellatorre N², Eisenberg D^{1,2}

¹Department of Surgery, Stanford University School of Medicine, Stanford, CA; and ²Department of Surgery, VA Palo Alto Health Care System, Palo Alto, CA

J Obes 2011 Dec 7; 2011: [Epub ahead of print]; DOI:10.1155/2011/350523

Background

Evaluation of the short-time effect of laparoscopic sleeve gastrectomy (LSG) in obese patients with T2D is mandatory.

Methods

In a prospective study of 178 patients subjected to LSG, age, gender, body mass index (BMI), diabetic medication use, glucose, insulin, and HbA1c levels were documented preoperatively and at 2 weeks, 2 months, 6 months, and 12 months postoperatively. Use and cost of diabetic medications were followed.

Results

Of 178 patients, 22 were diabetics who underwent LSG. Diabetes remission was observed in 62% of patients within 2 months and in 75% of patients within 12 months. Average number of diabetic medications decreased from 2.2 to <1 within 2 weeks after surgery; corresponding to a diabetes medication cost savings of 80%, 91%, 99%, and 99.7% after 2 weeks, 2 months, 6 months, and 12 months, respectively.

Conclusion

Patients with T2D and morbid obesity who undergo LSG have high rates of diabetes remission early after surgery, with a significant medication cost savings.

Incorporating indirect costs into a cost-benefit analysis of laparoscopic adjustable gastric banding

Finkelstein EA¹, Allaire BT², Dibonaventura MD³, Burgess SM⁴

¹Duke-NUS Graduate Medical School, Singapore; ²RTI International, Research Triangle Park, NC; ³Health Sciences Practice, Kantar Health, New York, NY; and ⁴Global Health Outcomes Strategy and Research, Allergan Inc., Irvine, CA

Value Health 2012; **15**: 299–304

Background

This study estimated the time to breakeven and the five-year net costs of laparoscopic adjustable gastric banding (LAGB), taking into account both direct and indirect costs and cost savings from the literature.

Methods

Total savings were calculated based on quantifying relationships between medical expenditures, absenteeism, and presenteeism. These savings were then combined with the direct and indirect costs to quantify net savings.

Results

Including indirect costs after five years, net savings in medical expenditures from a gastric banding procedure were estimated to be \$4,970 ($\pm$ \$3,090). Including absenteeism increased savings to \$6,180 ($\pm$ \$3,550). Savings were further increased to \$10,960 ($\pm$ \$5,864) when both absenteeism and presenteeism estimates were included.

Conclusions

This is an important contribution because the authors examined more than direct costs but included improvements in performance at work, noting that inclusion of these data documented even greater cost advantages for bariatric surgery.

Impact of bariatric surgery on health care utilization and costs among patients with diabetes

Bleich SN¹, Chang HY¹, Lau B^{2,3}, Steele K⁴, Clark JM^{2,3}, Richards T¹, Weiner JP¹, Wu AW^{1,2,3,4}, Segal JB^{1,2,3}

¹Department of Health Policy and Management, ²Department of Epidemiology, ³Department of Medicine, ⁴Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD

Med Care 2012; **50**: 58–65

Background

There is no clear data about the impact of bariatric surgery on healthcare utilization in patients with T2D.

Methods

Healthcare utilization and costs in an insured cohort of 7,806 individuals with T2D after bariatric surgery were derived from administrative data from 2002 to 2008 from seven Blue Cross Blue Shield Plans.

Results

If the cost of the bariatric surgery was excluded, hospital costs were higher in year two after surgery. However, in terms of having any healthcare costs, those costs were lower after surgery as well. However for those requiring hospitalization, the ratio of inpatient days was higher.

Conclusion

Individuals with T2D did not have lower healthcare costs in the six years after surgery.

Comment

Is bariatric surgery cost-effective?

The third essential element for a successful medical therapy, in addition to efficacy and safety, is “efficiency” (i.e., the use of resources and/or “cost”). However, evaluation of cost is difficult due to the many confounding variables: 1) charges do not necessarily reflect costs; 2) costs and outcomes vary by region, by hospitals, by providers, by carriers, by age, by race, by the economic and educational status of the patients, by the stages of the diseases and co-morbidities; and 3) it is difficult to determine the costs and values of favorable results such as (a) the reduction of disabilities due to the loss of weight, (b) the value of return to employment or studies, and (c) the pursuit of remedial procedures, such as hip replacement, transplant, or plastic surgery. For example, how can one calculate the cost and value of the gastric bypass performed on Mr. Al Roker, the popular WNBC-TV weatherman who, reportedly, was only able to climb three steps due to his weight and heart failure prior to his operation on March 22, 2002? He is now able to pursue a highly successful and well-paid career.

The above four important articles have added to our knowledge about the economics of obesity and bariatric surgery this year. The first three papers support the general impression reflected in the literature over the last 10 years, that bariatric surgery reduces healthcare expenditures with a return of the costs over the following two to three years. The fourth paper documents again how difficult these studies are. The BCBS study was limited to in-hospital costs and failed to address the considerable costs incurred from knee replacements, hip replacements, plastic surgery, and other corrective operations that only became possible after bariatric surgery.

Physicians' attitudes about referring their type 2 diabetes patients for bariatric surgery

Sarwer DB^{1,2}, Ritter S¹, Wadden TA¹, Spitzer JC¹, Vetter ML³, Moore RH^{1,4}

¹Department of Psychiatry, ²Department of Surgery, ³Department of Medicine, ⁴Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

Surg Obes Relat Dis 2012; **Jul–Aug**; **8**: 381–6

Background

Little data is available about the physician's attitudes toward treatment of bariatric surgery in patients with T2D.

Methods

Physicians at an academic medical center (n=142) and community-based physicians (n=197) in the Philadelphia area in specialties likely to treat T2D were sent a survey about their perceptions of the safety and efficacy of bariatric surgery as a treatment for obesity and T2D.

Results

With a combined response rate of 27.4%, physicians reported having positive impressions of bariatric surgery as a treatment for obesity and T2D (79.6% and 67.4%, respectively). Yet only 20.8% of respondents indicated that they would be likely to refer their patients with T2D with a BMI of 30–34.9 kg/m² to a randomized research trial of bariatric surgery.

Conclusions

Physicians who treat patients with T2D and obesity had favorable impressions about bariatric surgery as a treatment. However, only a small percentage of them were willing to refer the patients with T2D and obesity to randomized research trials of bariatric surgery. This reflects an important barrier to the successful completion of studies of the efficacy of bariatric surgery for those with T2D and a BMI <35 kg/m².

Comment

Why do less than one percent of those who would benefit utilize bariatric surgery?

The low utilization of bariatric surgery (i.e., less than 1% of the patients who could benefit undergo the surgery) continues to be a puzzle. The reason for lack of utilization of bariatric surgery is multifactorial. In our experience, physicians' attitudes are only a part of the challenge. Patients, themselves, have an aversion to undergoing surgery, especially to avert the complications of T2DM that may not appear for another decade. Also, many patients are frightened of the disasters of bariatric surgery that are reported in numerous media outlets, not understanding that the majority of outcomes are far different. The biggest hurdles, however, are the difficulties and delays in obtaining coverage by insurance carriers, often with requirements that are completely unfounded by the current literature, such as demands that the morbidly obese patients lose significant weight prior to getting approval for bariatric surgery. In patients who have unsuccessfully tried dieting for years, it is not surprising that many fail this cruel test and just give up.

Medicaid coverage has also been withdrawn in a number of states due to budget problems and perhaps bias against obesity, even though these operations are cost-effective.

Conclusions

It has taken over a half century to develop bariatric surgery to the point where even the original name, based on "baros" for weight, no longer fits. Although the four currently accepted procedures (the adjustable gastric band, the gastric sleeve, the gastric bypass, and the biliopancreatic bypass with duodenal switch) are indeed the most effective therapies for weight control, they also produce far more important health effects that include the remission of type 2 diabetes, hypertension, nonalcoholic steatohepatitis (NASH), gastroesophageal reflux (GERD), polycystic ovary syndrome (PCOS), asthma, cardiopulmonary failure, and even the sharp reduction in the prevalence of cancer. Accordingly, the new proposed name, "metabolic surgery," offers a far more fitting description.

The selected papers this year have made an important contribution. Together with other publications not noted here, the literature now offers strong support for the conclusion that bariatric surgery is effective; in fact, more effective than current medical therapies. In addition, the data show that the surgery is safe and cost-effective.

While this approbation of bariatric surgery is important, it is really only the start of the journey. We cannot announce success until we understand the pathways of the metabolic syndrome, until we can abandon surgical approaches for medical measures, and, even better, prevent the diseases. We have not completed our task. Although we have made significant strides to understanding the physiologic and metabolic changes that occur after bariatric surgery, we have a long way to go!

Author Disclosure Statement

W.H.C. and E.C. declare no potential conflicts of interest. W.J.P. receives grant support from the NIDDK/National Institutes of Health, Johnson & Johnson, and Glaxo SK.

Reference

1. MacDonald, KG, Long, SD, Swanson, MS, Brown, BM, Morris, PG, Dohm, GL and Pories, WJ. "The Gastric Bypass Operation Reduces the Progression and Mortality of Non-Insulin Dependent Diabetes Mellitus." *Journal of Gastrointestinal Surgery*. 1: 213–220, 1997.